TABLE 5.
Serum antibody responses to CS1 or CS3 measured by TRF ELISA after one or two doses of PTL-002 or PTL-003a
| Antibody | Vaccine | No. of respondersb (%) |
Total no. of respondersb (%) | Pc | |
|---|---|---|---|---|---|
| One-dose group | Two-dose group | ||||
| Anti-CS1 | |||||
| IgA | PTL-002 | 3/10 (30) | 3/10 (30) | 6/20 (30) | 0.11 |
| PTL-003 | 5/9 (56) | 6/11 (55) | 11/20 (55) | ||
| IgG | PTL-002 | 0/10 (0) | 2/10 (20) | 2/20 (10) | 0.66 |
| PTL-003 | 1/9 (11) | 3/11 (27) | 4/20 (20) | ||
| Anti-CS3 | |||||
| IgA | PTL-002 | 2/10 (20) | 3/10 (30) | 5/20 (25) | 0.03 |
| PTL-003 | 7/9 (78) | 6/11 (55) | 13/20 (65) | ||
| IgG | PTL-002 | 0/10 (0) | 2/10 (20) | 2/20 (10) | 0.03 |
| PTL-003 | 4/9 (44) | 5/11 (45) | 9/20 (45) | ||
| Anti-CS1 or anti-CS3 | |||||
| IgA | PTL-002 | 3/10 (30) | 4/10 (40) | 7/20 (35) | 0.03 |
| PTL-003 | 7/9 (78) | 8/11 (73) | 15/20 (75) | ||
| IgG | PTL-002 | 0/10 (0) | 3/10 (30) | 3/20 (15) | 0.02 |
| PTL-003 | 4/9 (44) | 7/11 (64) | 11/20 (55) | ||
a
Antibody levels were measured by time-resolved fluorescence. Response was defined as ≥2-fold increase compared to preimmune levels.
b
Number of subjects with a response/total number of subjects in group (%).
c
Chi-square or Fisher's exact test comparison of total responders to PTL-002 versus total responders to PTL-003.